Scientists develop promising drug candidates for pain, addiction

January 13, 2014

Scientists from the Florida campus of The Scripps Research Institute (TSRI) have described a pair of drug candidates that advance the search for new treatments for pain, addiction and other disorders.

The two new drug scaffolds, described in a recent edition of The Journal of Biological Chemistry, offer researchers novel tools that act on a demonstrated therapeutic target, the (KOR), which is located on nerve cells and plays a role in the release of the neurotransmitter dopamine. While compounds that activate KOR are associated with positive therapeutic effects, they often also recruit a molecule known as ╬▓arrestin2 (beta arrestin), which is associated with depressed mood and severely limits any therapeutic potential.

"Compounds that act at kappa receptors may provide a means for treating addiction and for treating pain; however, there is the potential for the development of depression or dysphoria associated with this receptor target," said Laura Bohn, a TSRI associate professor who led the study. "There is evidence that the negative feelings caused by kappa receptor drugs may be, in part, due to receptor actions through proteins called beta arrestins. Developing compounds that activate the without recruiting beta arrestin function may serve as a means to improve the therapeutic potential and limit side effects."

The new compounds are called "biased agonists," activating the receptor without engaging the beta arrestins.

Research Associate Lei Zhou, first author of the study with Research Associate Kimberly M. Lovell, added, "The importance of these biased agonists is that we can manipulate the activation of one particular signaling cascade that produces analgesia, but not the other one that could lead to dysphoria or depression."

The researchers note that the avoidance of depression is particularly important in , where can play a role in relapse.

The two also have a high affinity and selectivity for KOR over other and are able to pass through the blood-brain barrier. Given these promising attributes, the scientists plan to continue developing the compounds.

More information: "Development of Functionally Selective, Small Molecule Agonists at Kappa Opioid Receptors,"

Related Stories

Recommended for you

New method facilitates research on fuel cell catalysts

October 8, 2015

While the cleaning of car exhausts is among the best known applications of catalytic processes, it is only the tip of the iceberg. Practically the entire chemical industry relies on catalytic reactions. Therefore, catalyst ...

Better fluorescent lighting through physics

October 8, 2015

General Electric (GE), Lawrence Livermore National Laboratory (LLNL) and Oak Ridge National Laboratory (ORNL) have created new kinds of fluorescent lighting phosphors that use far less rare-earth elements than current technology.

Porous material holds promise for prosthetics, robots

October 8, 2015

Cornell researchers have developed a new lightweight and stretchable material with the consistency of memory foam that has potential for use in prosthetic body parts, artificial organs and soft robotics. The foam is unique ...


Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.